Early warning indicators for HIV drug resistance in cameroon during the year 2010

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Billong, Serge C ^a,b,c   Fokam, Joseph ^a,c,d   Nkwescheu, Armand S ^a,b,c   Kembou, Etienne ^a,e   Milenge, Pascal ^a,e   Tsomo, Zephirin ^a,f   Dion, Grace Ngute ^a,b,g   Aghokeng, Avelin F ^a,h   Mpoudi, Eitel N ^h   Ndumbe, Peter M ^c,d,i   Colizzi, Vittorio ^d,j   Nfetam, Jean B ^a,b  

^a National HIV Drug Resistance Surveillance and Prevention Working Group (HIVDR WG)   (Cameroon)

^b MINISTRY OF PUBLIC HEALTH   (Cameroon)

^c UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^d Laboratory of Systems Biology   (Cameroon)

^e World Health Organisation (WHO)   (Cameroon)

^f YAOUNDÉ CENTRAL HOSPITAL   (Cameroon)

^g YAOUNDÉ GENERAL HOSPITAL   (Cameroon)

^h Laboratory of Virology   (Cameroon)

ⁱ UNIVERSITY OF BUEA   (Cameroon)

^j UNIVERSITY OF ROME TOR VERGATA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL RESISTANCE; ARTICLE; CAMEROON; COMMUNITY CARE; DESCRIPTIVE RESEARCH; DRUG TREATMENT FAILURE; FOLLOW UP; HEALTH CARE PERSONNEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; PARAMEDICAL EDUCATION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; RETROSPECTIVE STUDY; DRUG EFFECT;

ANTI-HIV AGENTS; CAMEROON; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS;

EID: 84861203401     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036777     Document Type: Article

References (21)

1. Comité National de lutte contre le SIDA, (2009) Profil des estimations pays du VIH SIDA au Cameroun. Ministère de la Santé Publique du Cameroun. 01 Available: http://www.cnls.org/public/web/IMG/pdf/profil_des_estimations_et_projections_2010_2015.pdf. Accessed 2011 Aug 01.
2. World Health Organization and UNAIDS (2010) Guidelines on Estimating the Size of Populations Most at Risk to HIV. Geneva, World Health Organization. 01 Available: http://data.unaids.org/pub/Manual/2010/guidelines_popnestimationsize_en.pdf. Accessed 2010 Jun 01.
3. Ministère de la Santé Publique du Cameroun, (2010) Directives Nationales de Prise En Charge par les Antirétroviraux des Personnes (adultes et adolescents) Infectées par le VIH.
4. World Health Organization (2010) Antiretroviral therapy for HIV infection in infants and children: Towards universal access. Recommendations for a public health approach: 2010 revision. ISBN: 978 92 4 159980 1. 10 Available: http://www.who.int/hiv/pub/arv/adult2010/en/index.html. Accessed 2010 Dec 10.
5. HIV drug resistance working group, National AIDS control committee in Cameroon (2010) Guidelines for the evaluation of Early Warning Indicators for HIV drug resistance (EWI).
6. WHO/UNAIDS, (2003) The WHO and UNAIDS global initiative to provide antiretroviral therapy to 3 million people with HIV/AIDS in developing countries by the end of 2005. 05 Available: http://www.who.int/3by5/publications/documents/en.pdf. Accessed 2008 Aug 05.
7. World Health Organization (2010) Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-Limited Settings: Towards Universal Access: Recommendations for a public health approach. ISBN: 9789241599764. 10 Available: http://www.who.int/hiv/pub/arv/adult2010/en/index.html. Accessed 2010 Dec 10.
8. Bennett DE, (2006) The requirement for surveillance of HIV drug resistance within antiretroviral roll out in the developing world. Curr Opin Infect Dis. 19: 607-614.
9. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF, (2008) The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther. 13 (Suppl 2): 1-13.
10. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D, (2008) World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther. 13 (Suppl 2): 15-23.
11. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF, (2008) Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 13 (Suppl 2): 25-36.
12. Aghokeng FA, Vergne L, Mpoudi NE, Mbangue M, Deoudje N, et al. (2009) Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries Antiviral Therapy. 14: 401-411.
13. Kouanfack C, Montavon C, Laurent C, Aghokeng A, Kenfack A, et al. (2009) Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment. Clin Infect Dis. 48: 1318-1322.
14. Fokam J, Salpini R, Santoro MM, Cento V, Perno CF, et al. (2011) Drug Resistance Among Drug-naive and First-line Antiretroviral Treatment-failing Children in Cameroon. Pediatr Infect Dis J 2011; 30: 1062-1068 doi:10.1097/INF.0b013e31822db54c.
15. Yang C, McNulty A, Diallo K, Zhang J, Titanji B, et al. (2010) Development and Application of a Broadly Sensitive Dried-Blood-Spot-Based Genotyping Assay for Global Surveillance of HIV-1 Drug Resistance. JCM, Sept. 2010, p. 3158-3164 Vol. 48, No. 9; 0095-1137/10/$ 12.00 doi:10.1128/JCM.00564-10.
16. Fokam J, Salpini R, Santoro MM, Cento V, D'Arrigo R, et al. (2011) Performance evaluation of an in-house human immunodeficiency virus type-1 protease-reverse transcriptase genotyping assay in Cameroon. Arch Virol. 705, 982 DOI 10.1007/s00705-011-0982-3.
17. World Health Organization (2010) HIV Drug resistance Early Warning Indicators. World Health Organization indicators to monitor HIV drug resistance prevention at antiretroviral treatment sites. 3 Available: http://www.who.int/hiv/topics/drugresistance/hiv_dr_early_warning_indicators.pdf. Accessed 2010 Sept 3.
18. Hedt BL, Wadonda-Kabondo N, Makombe S, Harries AD, Schouten EJ, et al. (2009) Early warning indicators for HIV drug resistance in Malawi. Antiviral Therapy. 13 (Suppl 2): 69-75.
19. Hong SY, Jonas A, Dumeni E, Badi A, Pereko D, et al. (2010) Population-Based Monitoring of HIV Drug Resistance in Namibia with Early Warning Indicators. J Acquir Immune Defic Syndr. 55 (4): 27-31.
20. Comité Nationale de Lutte contre le SIDA au Cameroun, (2010) Proposition VIH du Cameroun-Série 10 (Global Fund Round 10). Accès universel pour la PTME, la prise en charge globale des PVVIH et la prevention du VIH auprès des populations les plus exposées au Cameroun. r10_ccm_cmr_h_pf_s1-2_20aug10_fr.
21. Boyer S, Eboko F, Camara M, AbéC Nguini MEO, et al. (2010) Scaling up access to antiretroviral treatment for HIV infection: the impact of decentralization of healthcare delivery in Cameroon. AIDS. 24 Suppl 1S, 5-15.